Matthew Macaluso – författare

This volume reviews the known neurobiology of depression and combines classic data on antidepressant treatments with modern theory on the physiology of depression. It also discusses novel mechanism of action drugs.

This book functions as a guide for leaders in academic and non-academic settings who are interested in developing, managing, or improving new or existing psychiatry residency programs. It notes the complexity of administering a residency program with ready solutions and tactics. 

Unique and comprehensive, this book contains chapters that focus on key areas of residency program management and innovation including but not limited to: meeting accreditation requirements, clinical and didactic curriculum, managing resident and faculty performance issues, research and scholarly activity in residency programs, rural training programs, and faculty development.

Graduate Medical Education in Psychiatry is an invaluable resource for medical education leaders, as well as trainees and those interested in psychiatric residency or academic psychiatry in general.

The book reviews clinical trial methodology as it pertains to drug development in psychiatry. The reader will understand the process of drug development in psychiatry from discovery through marketing with the help of clinically relevant examples. The reader will appreciate the history of drug development in psychiatry dating back to the era of serendipitous discovery and culminating in an era of new and highly focused targets. Readers will understand how drug development in psychiatry has changed and adapted with the discovery of novel mechanism of action drugs. Novel drugs and disease targets have changed the way developers and regulatory agencies think about clinical trial methodology.

The book elucidates how biomarkers, genetics and advances in neuroscience and neuroimaging have influenced drug development approaches, which will ultimately change the practice of psychiatry. The book will be broken down into the following sections:

a.        Prior to the 1960s - Drug discovery by chance observation

b.       The last 50 years – refined targeting of CNS drugs without the discovery of mechanistically new drugs

c.       The future – the discovery and development of mechanistically new drugs. The examination of new targets, genetics and biomarkers.